Notice: This company has been marked as potentially delisted and may not be actively trading. Yumanity Therapeutics (YMTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrends YMTX vs. EQ, LGVN, ENLV, ESLA, NAII, MIRA, ICCC, INKT, ITRM, and PLURShould you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Equillium (EQ), Longeveron (LGVN), Enlivex Therapeutics (ENLV), Estrella Immunopharma (ESLA), Natural Alternatives International (NAII), MIRA Pharmaceuticals (MIRA), ImmuCell (ICCC), MiNK Therapeutics (INKT), Iterum Therapeutics (ITRM), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry. Yumanity Therapeutics vs. Equillium Longeveron Enlivex Therapeutics Estrella Immunopharma Natural Alternatives International MIRA Pharmaceuticals ImmuCell MiNK Therapeutics Iterum Therapeutics Pluri Equillium (NASDAQ:EQ) and Yumanity Therapeutics (NASDAQ:YMTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk. Do institutionals and insiders believe in EQ or YMTX? 27.0% of Equillium shares are held by institutional investors. Comparatively, 25.1% of Yumanity Therapeutics shares are held by institutional investors. 30.3% of Equillium shares are held by insiders. Comparatively, 12.5% of Yumanity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer EQ or YMTX? Equillium currently has a consensus price target of $5.00, indicating a potential upside of 565.42%. Given Equillium's stronger consensus rating and higher probable upside, equities research analysts clearly believe Equillium is more favorable than Yumanity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Yumanity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor EQ or YMTX? Equillium received 22 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. Likewise, 83.72% of users gave Equillium an outperform vote while only 70.00% of users gave Yumanity Therapeutics an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3683.72% Underperform Votes716.28%Yumanity TherapeuticsOutperform Votes1470.00% Underperform Votes630.00% Which has preferable earnings & valuation, EQ or YMTX? Equillium has higher revenue and earnings than Yumanity Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$42.62M0.62-$13.34M-$0.25-3.01Yumanity Therapeutics$4.84M0.00-$39.50M-$3.00N/A Is EQ or YMTX more profitable? Equillium has a net margin of -19.51% compared to Yumanity Therapeutics' net margin of -660.61%. Equillium's return on equity of -36.88% beat Yumanity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Equillium-19.51% -36.88% -17.31% Yumanity Therapeutics -660.61%-263.34%-107.08% Does the media refer more to EQ or YMTX? In the previous week, Equillium had 11 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 11 mentions for Equillium and 0 mentions for Yumanity Therapeutics. Yumanity Therapeutics' average media sentiment score of 0.00 beat Equillium's score of -0.03 indicating that Yumanity Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Equillium Neutral Yumanity Therapeutics Neutral Which has more volatility and risk, EQ or YMTX? Equillium has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Yumanity Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. SummaryEquillium beats Yumanity Therapeutics on 15 of the 17 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Yumanity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart YMTX vs. The Competition Export to ExcelMetricYumanity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.46M$6.96B$5.30B$8.82BDividend YieldN/A7.97%5.17%4.03%P/E Ratio-0.248.96117.0716.55Price / SalesN/A418.85674.70103.32Price / CashN/A22.5535.0531.65Price / BookN/A5.514.735.23Net Income-$39.50M$154.47M$115.11M$224.13M Yumanity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)YMTXYumanity TherapeuticsN/AN/AN/AN/A$7.46M$4.84M-0.2440Gap DownEQEquillium2.4918 of 5 stars$0.83-3.5%N/A+51.8%$29.40M$36.08M-3.3240Upcoming EarningsNews CoverageGap DownLGVNLongeveron3.1256 of 5 stars$2.03-2.9%N/A-88.9%$29.15M$710,000.00-0.2323Upcoming EarningsAnalyst ForecastENLVEnlivex Therapeutics3.4468 of 5 stars$1.36+0.7%N/A-36.8%$29.12MN/A-1.1570Upcoming EarningsESLAEstrella Immunopharma0.6556 of 5 stars$0.73-8.8%N/A-43.6%$28.95MN/A-0.37N/APositive NewsGap DownNAIINatural Alternatives International1.9393 of 5 stars$4.55-0.4%N/A-26.5%$28.21M$113.80M-3.70290Upcoming EarningsGap UpMIRAMIRA Pharmaceuticals2.7211 of 5 stars$1.90-13.2%N/A+19.7%$28.08MN/A-2.792Upcoming EarningsICCCImmuCellN/A$3.58-0.8%N/A-32.6%$28.04M$23.22M-6.7575Upcoming EarningsPositive NewsINKTMiNK Therapeutics1.8091 of 5 stars$0.71-1.4%N/A-39.5%$28.03MN/A-1.4530Upcoming EarningsITRMIterum Therapeutics2.4449 of 5 stars$1.22-5.4%N/A+58.4%$27.71MN/A-0.6110Upcoming EarningsGap UpHigh Trading VolumePLURPluri0.4614 of 5 stars$4.85-3.2%N/A+6.0%$26.53M$330,000.00-0.82150Upcoming EarningsGap Up Related Companies and Tools Related Companies Equillium Alternatives Longeveron Alternatives Enlivex Therapeutics Alternatives Estrella Immunopharma Alternatives Natural Alternatives International Alternatives MIRA Pharmaceuticals Alternatives ImmuCell Alternatives MiNK Therapeutics Alternatives Iterum Therapeutics Alternatives Pluri Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:YMTX) was last updated on 11/7/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Yumanity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Yumanity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMTX Stock Alerts